Alexion Pharma Shareholders Approve Acquisition By AstraZeneca

Alexion Pharmaceuticals Inc. (ALXN) said that its shareholders have approved proposed acquisition by AstraZeneca Plc. (AZN.L,AZN). The acquisition is expected to close in the third quarter of 2021.

In December 2020, AstraZeneca agreed to buy Alexion for $175 per share in cash and stock, valuing the Boston-based company at $39 billion.

As per the terms of the deal, Alexion shareholders would receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares or ADSs for each Alexion share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google has revoked its three-year ban on cryptocurrency-related ads on its sites under the search giants' new ad services policy. This action will now allow cryptocurrency exchanges and wallets certified by Google to advertise their products and services on Google's network, beginning August 3, 2021. The UK's competition regulator said Friday that it has secured commitments from Google to address concerns about the tech giant's proposal to remove third-party cookies from Chrome browser. Archer Aviation, a developer of electric vertical take-off and landing or eVTOL aircraft, unveiled its autonomous electric two-seater aircraft, named "Maker", marking a milestone towards its commercial launch. The California-based air mobility company, which has already received orders from United Airlines, will use its inaugural aircraft prototype for testing as it works towards certification.
Follow RTT